<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="mutate">
            <roleset id="Mutate.01" name="" wordnet="1">
                <roles>
                    <role n="0" descr="physical location where mutation happen// exon, intron //&#x0A;" />
                    <role n="1" descr="mutated entity   // gene //&#x0A;" />
                    <role n="2" descr="changes at molecular level/* always use prepositional phrase */&#x0A;" />
                    <role n="3" descr="changes at phenotype level /* secondary predication */  &#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, essentially mutating to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutating as an essential factor for abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>A1 gene that can be mutated into ceroid variety of late infertile neural diffuscosis (CLN6) and in nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid variety of late infertile neural diffuscosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>A1 mutation (EE amino acids(437 and 438) in AA is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with sequences of Dam targets mutated support this conclusion.</text>
                    <arg n="1">sequences of Dam targets</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with sequences of Dam targets that are mutated support this conclusion.</text>
                    <arg n="1">sequences of Dam targets</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with sequences of Dam targets that have been mutated support this conclusion.</text>
                    <arg n="1">sequences of Dam targets</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Analyses of the in vivo transcription of Agn-lacZ with sequences of Dam targets that were mutated support this conclusion.</text>
                    <arg n="1">sequences of Dam targets</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>Analyses of the in vivo transcription of agn-lacZ with sequences of Dam targets that can be mutated support this conclusion.</text>
                    <arg n="1">sequences of Dam targets</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>Analyses of the in vivo transcription of agn-lacZ with sequences of Dam targets that may have been mutated support this conclusion.</text>
                    <arg n="1">sequences of Dam targets</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>Analysis of the in vivo transcription of agn-lacZ with A1 mutated (target sequences Dam) supports this conclusion.</text>
                </example>
                <example src="EGRAM" no="11">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (Mutated WT-1 Form), p53 and a Mutated p53 revealed a complex regulatory pattern with 3-fold induction with WT-1, 7-fold induction with p53 that could be mutated and 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">7-fold induction</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (Mutated WT-1 Form), p53 and a Mutated p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, 7-fold induction with p53 that is able to be mutated and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">7-fold induction</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (WT-1 mutated form), p53 and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, 7-fold induction with p53 that has the ability to be mutated remarkably and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">7-fold induction</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that can be mutated remarkably and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that can be mutated sharply, and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that can be mutated, and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that can be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that could be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that has the ability to be mutated and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that has the ability to be mutated and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that has the ability to be mutated remarkably and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is able to be mutated and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is able to be mutated remarkably and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is believed to be mutated markedly, and a 4-fold repression with A0 wild (p53).</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is believed to be mutated markedly, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is believed to be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is observed to be mutated sharply, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is observed to be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that may have been mutated sharply, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that may have been mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that was mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that will be mutated and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that will be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that would be mutated remarkably and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>Cotransfections with plasmids that express WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that would be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>For example, it is observed that mutating the MAP-terminal T235 and T239 sites essentially leads to abolition the stimulated increase of EGF in phosphorylation and avoidance of the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and avoidance of the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>For example, mutating the MAP-terminal T235 and T239 sites has essentially led to abolition the stimulated increase in GEGF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase in GEGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>For example, the A0 mutation (local C-terminal kinase site of MAP (T235 and T239) essentially led to abolited EGF increase and increased EGF-induced phosphorylation and mobility (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutating to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>For example, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239)) is essentially the one that mutate to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutate to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>For example, the A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239) essentially mutating to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>For example, the A0 mutation (the sites of MAP C-terminal kinase (T235 and T239) could mutate essentially led to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) essentially led to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutate 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) may mutate essentially led to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) was essentially responsible for abolition of FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>For example, the A0 mutation (the sites of the C-terminal kinase of PAM (T235 and T239) may mutating essentially led to abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of EGF-stimulated phosphorylation and EGF-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>For example, the A0 mutation (the sites of the PAM C-terminal kinase (T235 and T239) could mutating essentially led to the increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the increased phosphorylation stimulated by EGF and change of mobility induced by the EGF</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>However, the mutation of MAP-terminal the T235 and T239 sites essentially mutating to abolition the stimulated increase of the EGF in phosphorylation and preventing the change in mobility introduced by the EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of the EGF in phosphorylation and preventing the change in mobility introduced by the EGF</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>In COS-7 cell cotransfects with plasma expression PKA-Calfa and SOX9, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) could have already been mutated)</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>In COS-7 cells co-transfected with PKA-Calfa and SOX9 expression plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two PKA phosphorylation sites (S (64) and S (211)) were observed to be significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="55">
                    <text>In COS-7 cells co-transfected with PKA-Calfa and SOX9 expression plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) in which A1 (the two PKA phosphorylation sites (S (64) and S (211) were significantly mutated.</text>
                </example>
                <example src="EGRAM" no="56">
                    <text>In COS-7 cells co-transfected with PKA-Calfa and SOX9 expression plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two PKA phosphorylation sites (S (64) and S (211)) are significantly mutated.</text>
                </example>
                <example src="EGRAM" no="57">
                    <text>In COS-7 cells that co-transfect with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) in which A1 (the two phosphorylation sites PKA (S 64) and S (211) could have been significantly mutated.</text>
                </example>
                <example src="EGRAM" no="58">
                    <text>In COS-7 cells that co-transfect with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) in which A1 (the two phosphorylation sites PKA (S 64) and S (211) were mutated.</text>
                </example>
                <example src="EGRAM" no="59">
                    <text>In COS-7 cells that co-transfect with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) in which A1 (the two phosphorylation sites PKA (S 64) and S (211) were significantly mutated.</text>
                </example>
                <example src="EGRAM" no="60">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) in which A1 (the two phosphorylation sites PKA (S 64) and S (211) were mutated as mutations.</text>
                </example>
                <example src="EGRAM" no="61">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two phosphorylation sites PKA (S 64) and S (211) are able to be mutated.</text>
                </example>
                <example src="EGRAM" no="62">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two phosphorylation sites PKA (S 64) and S (211) are able to be significantly mutated.</text>
                </example>
                <example src="EGRAM" no="63">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two phosphorylation sites PKA (S 64) and S (211) are mutated.</text>
                </example>
                <example src="EGRAM" no="64">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two phosphorylation sites PKA (S 64) and S (211) have the ability to mutated.</text>
                </example>
                <example src="EGRAM" no="65">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two phosphorylation sites PKA (S 64) and S (211) may have been mutated.</text>
                </example>
                <example src="EGRAM" no="66">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 expressing plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two phosphorylation sites PKA (S 64) and S (211) may have been significantly mutated.</text>
                </example>
                <example src="EGRAM" no="67">
                    <text>In COS-7 cells, co-transfects with PKA-Calfa and SOX9 mutated plasmids, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where the two phosphorylation sites PKA (S 64) and S (211) may have been mutated.</text>
                    <arg n="1">the two phosphorylation sites PKA (S 64) and S (211) may have been mutated</arg>
                </example>
                <example src="EGRAM" no="68">
                    <text>In COS-7 cells, co-transfects with the expression mutated PKA-Calfa and SOX9, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where the two phosphorylation sites PKA (S 64) and S (211) have already been mutated.</text>
                    <arg n="1">the two phosphorylation sites PKA (S 64) and S (211) have already been mutated</arg>
                </example>
                <example src="EGRAM" no="69">
                    <text>In COS-7 cells, co-transfects with the expression plasmids PKA-Calfa and SOX9, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) in which A1 (the two phosphorylation sites PKA (S 64) and S (211) were mutated.</text>
                </example>
                <example src="EGRAM" no="70">
                    <text>In COS-7 cells, co-transfects with the expression plasmids PKA-Calfa and SOX9, PKA improved the phosphorylation of wild SOX9, but did not affect the phosphorylation of an A0 protein (SOX9) where A1 (the two phosphorylation sites PKA (S 64) and S (211) have already been significantly mutated.</text>
                </example>
                <example src="EGRAM" no="71">
                    <text>In COS-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) were significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="72">
                    <text>In COS-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which it was observed that A1 (the two phosphorylation sites PKA (S (64) and S (211) were significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="73">
                    <text>In contrast, A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) essentially mutate to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="74">
                    <text>In contrast, mutate the T235 and T239 sites essentially leads to abolition of the FEG-stimulated increase in phosphorylation and prevention of FEG-induced mobility change (picture 5C, bands 7 and 8).</text>
                    <arg n="0">the T235 and T239 sites</arg>
                    <arg n="2">abolition of the FEG-stimulated increase in phosphorylation and prevention of FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="75">
                    <text>In contrast, the A0 mutation (the C-terminal kinase sites of MAP (T235 and T239) was essentially the one that led to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutate 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="76">
                    <text>In contrast, the A0 mutation (the sites of MAP C-terminal kinase (T235 and T239) essentially led to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutate 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="77">
                    <text>In contrast, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) essentially led to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutate 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="78">
                    <text>In contrast, the A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) may mutate essentially led to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="79">
                    <text>In contrast, the A0 mutation (the sites of the MAP terminal C-kinase (T235 and T239) may mutate essentially led to increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the increase in phosphorylation stimulated by FEG and change in mobility induced by FEG</arg>
                </example>
                <example src="EGRAM" no="80">
                    <text>In contrast, the MAP-terminal T235 and T239) mutate essentially leads to abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="2">abolished the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="81">
                    <text>In cos-7 cells cotransfects with plasmid expression PKA-Calfa and SOX9, PKA improved the phosphorylation of wild type SOX9 but did not affect the phosphorylation of an SOX9 protein in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated.</text>
                    <arg n="0">SOX9 protein</arg>
                </example>
                <example src="EGRAM" no="82">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (64) and S (211) have the ability to mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="83">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) are significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="84">
                    <text>In cos-7 cotransfect cells with plasma expression PKA-Calfa and SOX9, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which the two phosphorylation sites PKA (S (64) and S (211) have already been mutated).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have already been mutated)</arg>
                </example>
                <example src="EGRAM" no="85">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) could have already been significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="86">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) could have been mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="87">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) could have been significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="88">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) have already been significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="89">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) were mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="90">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which A1 (the two phosphorylation sites PKA (S (64) and S (211) were significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="91">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 in which it was observed that A1 (the two phosphorylation sites PKA (S (64) and S (211) were mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="92">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) are mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="93">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) can be mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="94">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA improved the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where A1 (the two phosphorylation sites PKA (S (64) and S (211) can be significantly mutated.</text>
                    <arg n="0">SOX9</arg>
                </example>
                <example src="EGRAM" no="95">
                    <text>In cos-7 cotransfects with plasma expression PKA-Calfa and SOX9, PKA mutated the phosphorylation of the wild type SOX9, but did not affect the phosphorylation of a protein SOX9 where the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated).</text>
                    <arg n="0">SOX9</arg>
                    <arg n="1">the two phosphorylation sites PKA (S (64) and S (211) have the ability to be significantly mutated)</arg>
                </example>
                <example src="EGRAM" no="96">
                    <text>In order to mutate the MAP-terminal T235 and T239 sites, however, it essentially leads to abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="97">
                    <text>In order to mutate the MAP-terminal T235 and T239 sites, however, it has essentially led to abolition the stimulated increase in GF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase in GF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="98">
                    <text>In order to mutate the MAP-terminal T235 and T239 sites, however, it is observed that it essentially leads to abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="99">
                    <text>Induction of a mutation in the A0 gene (LacI) can mutated in loss of transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="100">
                    <text>Induction of a mutation in the A0 gene (LacI) has the ability to mutated in loss of transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="101">
                    <text>Induction of a mutation in the A0 gene (LacI) in contrast can mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="102">
                    <text>Induction of a mutation in the A0 gene (LacI) in contrast may mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="103">
                    <text>Induction of a mutation in the A0 gene (LacI) is able to mutated in loss of transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="104">
                    <text>Induction of a mutation in the A0 gene (LacI) may have mutated in loss of transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="105">
                    <text>Induction of a mutation in the A0 gene (LacI) may have mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="106">
                    <text>Induction of a mutation in the A0 gene (LacI) results in loss of transcriptional repression of the lacZ gene that mutated a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="107">
                    <text>Induction of a mutation in the A0 gene (LacI) results in loss of transcriptional repression of the lacZ gene that mutated the cellular mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="108">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, can mutated in losing the transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="109">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, has resulted in loss of transcriptional repression of the lacZ gene being a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="110">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, has the ability to mutated in loss of transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="111">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, may have mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="112">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="113">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, results in losing the transcriptional repression of the lacZ gene that mutated a mutated cell.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="114">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, results in loss of transcriptional repression of the lacZ gene that mutated a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="115">
                    <text>Induction of a mutation in the A0 gene (LacI), for example, will mutated in loss of transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="116">
                    <text>Induction of a mutation in the A0 gene (LacI), however, can mutated in losing the transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="117">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, could mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="118">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, has the ability to mutated in the loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="119">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, is able to mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="120">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, may have mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="121">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, may have mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                </example>
                <example src="EGRAM" no="122">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, mutated in losing the transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">losing the transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="123">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="124">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, results in loss of transcriptional repression of the lacZ gene, which mutated a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="125">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, results in loss of transcriptional repression of the lacZ gene, which mutated the cell mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="126">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="127">
                    <text>Induction of a mutation in the A0 gene (LacI), in contrast, will mutated in loss of transcriptional repression of the lacZ gene, which is the cellular mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="128">
                    <text>Induction of a mutation in the A0 gene (LacI), instead, results in loss of transcriptional repression of the lacZ gene, which mutated the cellular mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="129">
                    <text>Induction of a mutation in the A0 gene (LacI), on the other hand, has the ability to mutated in loss of transcriptional repression of the lacZ gene, which is the cellular mutation.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="130">
                    <text>It is likely that the model fragrances is significantly mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="131">
                    <text>It was observed that exon 5 mutated allele with the termination of the premature translation and resulted in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="132">
                    <text>Model fragments are able to be significantly mutated by the sequence of SAP97 RAT, adherence no.Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="133">
                    <text>Model fragments are mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="134">
                    <text>Model fragments are observed as mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="135">
                    <text>Model fragments are significantly mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="136">
                    <text>Model fragments can be mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="137">
                    <text>Model fragments can be significantly mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="138">
                    <text>Model fragments could be mutated by the sequence of SAP97 RAT , adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="139">
                    <text>Model fragments could be significantly mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="140">
                    <text>Model fragments could have been mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="141">
                    <text>Model fragments could have been significantly mutated by the sequence of SAP97 RAT, adherence no.Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="142">
                    <text>Model fragments has the probability of being mutations by the sequence of SAP97 RAT, adherence to Q62696 mutated the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="143">
                    <text>Model fragments is able to be mutated by the SAP97 RAT sequence, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="144">
                    <text>Model fragments may have been significantly mutated by the sequence of SAP97 RAT, adherence to Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="145">
                    <text>Model fragments will be mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="146">
                    <text>Model fragments will be significantly mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="147">
                    <text>Model fragments would be mutated by the sequence of SAP97 RAT , adherence in Q62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="148">
                    <text>Model fragments would be significantly mutated by the sequence of SAP97 RAT, adherence in Q62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Model fragments</arg>
                    <arg n="1">the sequence of SAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="149">
                    <text>Mutation A1 (EE(437 and 438) to A2 amino acids (AA) can mutating the DNA-binding mutant (Stat5aEE-A2 (AA) of Stat5a.</text>
                </example>
                <example src="EGRAM" no="150">
                    <text>Muting A1 (EE(437 and 438) in AA has the ability to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="151">
                    <text>Muting A1 (EE(437 and 438) to AA would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="152">
                    <text>Muting EE(437 and 438) to AA has the ability to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="1">EE(437 and 438)</arg>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="153">
                    <text>Our research has shown that mutating the C-terminal MAP kinase sites (T235 and T239) has essentially led to abolition the stimulated increase in EGF phosphorylation and preventing the change in mobility introduced by the EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolition the stimulated increase in EGF phosphorylation and preventing the change in mobility introduced by the EGF</arg>
                </example>
                <example src="EGRAM" no="154">
                    <text>Our research has shown that mutating the C-terminal MAP kinase sites (T235 and T239) may have essentially led to abolition the stimulated increase in EGF phosphorylation and preventing the change in mobility introduced by the EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the C-terminal MAP kinase sites (T235 and T239)</arg>
                    <arg n="2">abolition the stimulated increase in EGF phosphorylation and preventing the change in mobility introduced by the EGF</arg>
                </example>
                <example src="EGRAM" no="155">
                    <text>Our study mutate that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially led to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="156">
                    <text>Our study mutating that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially leads to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="157">
                    <text>Our study mutating that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially led to abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolition of FEG-stimulated phosphorylation and prevented FEG-induced mobility</arg>
                </example>
                <example src="EGRAM" no="158">
                    <text>Our study mutating that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) is essentially the one that leads to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="159">
                    <text>Our study mutating that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially led to above FEG-stimulated phosphorylation and FEG-induced mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">above FEG-stimulated phosphorylation and FEG-induced mobility</arg>
                </example>
                <example src="EGRAM" no="160">
                    <text>Our study mutating that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) is essentially the one that leads to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="161">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) essentially mutate to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="162">
                    <text>Our study showed that A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) may mutate essentially led to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="163">
                    <text>Our study showed that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) is essentially the one that mutate to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="164">
                    <text>Our study showed that the A0 mutation (the C-terminal sites of MAP kinase (T235 and T239) is essentially the one that mutate to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="165">
                    <text>PDK1 phosphorylation has not been altered by treatment of cells with a growth factor similar to insulin-I and four sites are remarkably mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="166">
                    <text>PDK1 phosphorylation has not been altered by treatment of cells with a growth factor similar to insulin-I and four sites will be mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="167">
                    <text>PDK1 phosphorylation has not been mutated by treatment of cells with a growth factor similar to insulin-I and four sites are mutations without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="168">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin I and four of the sites could be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="169">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin I and four of the sites have the ability to be remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="170">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin I and four of the sites may have been notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="171">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin I and four of the sites, as we predicted, are remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="172">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites are mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="173">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites are notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="174">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites can be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="175">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites can be notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="176">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites could be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="177">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites could have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="178">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites have been notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="179">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites have the ability to be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="180">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites is observed to mutated noticeably without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="181">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites were mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="182">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites were notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="183">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites will be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="184">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four of the sites will be notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="185">
                    <text>PDK1 phosphorylation was not altered by the treatment of cells with a growth factor similar to insulin-I and four sites, as suggested by our study, and can be mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="186">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites could have been notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="187">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as suggested by our study, have the ability to be mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="188">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as suggested by our study, it could have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="189">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as suggested by our study, it may have been mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="190">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as suggested by our study, mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="191">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as suggested by our study, they are observed to mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="192">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as suggested by our study, they have mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="193">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, are capable of being notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="194">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, are notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="195">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, could be notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="196">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, have mutated noticeably without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="197">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, have the ability to be notably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="198">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, it could have been remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="199">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, may have been remarkably mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="200">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, mutated noticeably without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="201">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin I and four of the sites, as we predicted, will mutated noticeably without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="202">
                    <text>PDK1 phosphorylation was not altered by treating cells with a growth factor similar to insulin-I and four of the sites have mutated without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="203">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with a growth factor similar to insulin I and four sites, as we have predicted, are markedly mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="204">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with a growth factor similar to insulin-I and four sites could be mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="205">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with a growth factor similar to insulin-I and four sites have the ability to be mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="206">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with a growth factor similar to insulin-I and four sites may have been mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="207">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with a growth factor similar to insulin-I and four sites were markedly mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="208">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with a growth factor similar to insulin-I and four sites were mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="209">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) are able to be mutated remarkably without loss of activity.</text>
                </example>
                <example src="EGRAM" no="210">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) are able to be mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="211">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) could have been mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="212">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) have the ability to be mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="213">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) were mutated with no loss of activity.</text>
                </example>
                <example src="EGRAM" no="214">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) were mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="215">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites) were observed to be mutated sharply without loss of activity.</text>
                </example>
                <example src="EGRAM" no="216">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites), as suggested by our study, and will be mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="217">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites), as suggested by our study, are able to be mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="218">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites), as we predicted, are markedly mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="219">
                    <text>PDK1 phosphorylation was not altered by treatment of cells with insulin-I and A0-like growth factor (four sites), as we predicted, were markedly mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="220">
                    <text>PDK1 phosphorylation was not altered with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, and can be mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="221">
                    <text>PDK1 phosphorylation was not altered with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, and could have been mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="222">
                    <text>PDK1 phosphorylation was not altered with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, and may have been mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="223">
                    <text>PDK1 phosphorylation was not altered with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, has the ability to be mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="224">
                    <text>PDK1 phosphorylation was not altered with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="225">
                    <text>PDK1 phosphorylation was not altered with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, they were mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="226">
                    <text>PDK1 phosphorylation was not mutated by the treatment of cells with a growth factor similar to insulin-I and four of the sites mutates are observed without loss of activity.</text>
                    <arg n="0">four of the sites</arg>
                </example>
                <example src="EGRAM" no="227">
                    <text>PDK1 phosphorylation was not mutated by the treatment of cells with a growth factor similar to insulin-I and four sites will be changed with emphasis without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="228">
                    <text>PDK1 phosphorylation was not mutated by the treatment of cells with a growth factor similar to insulin-I and four sites, as predicted and can be mutated noticeably without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="229">
                    <text>PDK1 phosphorylation was not mutated by the treatment of cells with a growth factor similar to insulin-I and four sites, as predicted, and may have been markedly mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="230">
                    <text>PDK1 phosphorylation was not mutated by the treatment of insulin-like growth factor cells and four sites could have been noticeably mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="231">
                    <text>PDK1 phosphorylation was not mutated by the treatment of insulin-like growth factor cells and four sites may have been noticeably mutated without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="232">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with a growth factor similar to insulin-I and four sites mutants are observed without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="233">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with growth factor similar to insulin-I and four sites, as predicted, and it was able to be changed remarkably without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="234">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with growth factor similar to insulin-I and four sites, as we predicted, has the ability to be changed remarkably without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="235">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with insulin-I and A0-like growth factor (four sites) can be remarkably mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="236">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with insulin-I and A0-like growth factor (four sites), as suggested by our study, are mutations without loss of activity.</text>
                </example>
                <example src="EGRAM" no="237">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with insulin-I and A0-like growth factor (four sites), as we predicted, could have been markedly mutated without loss of activity.</text>
                </example>
                <example src="EGRAM" no="238">
                    <text>PDK1 phosphorylation was not mutated by treatment of cells with insulin-I and A0-like growth factor (four sites), as we predicted, will be changed remarkably without loss of activity.</text>
                </example>
                <example src="EGRAM" no="239">
                    <text>PDK1 phosphorylation was not mutated with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, it will change without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="240">
                    <text>PDK1 phosphorylation was not mutated with the treatment of cells with a growth factor similar to insulin I and four sites, as suggested by our study, they are observed to change without loss of activity.</text>
                    <arg n="0">four sites</arg>
                </example>
                <example src="EGRAM" no="241">
                    <text>Plasmid cotransfections expressed by WT-1, ATPR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="242">
                    <text>Plasmid cotransfections expressed by WT-1, ATPR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that could have been mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="243">
                    <text>Plasmid cotransfections expressed by WT-1, ATPR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="244">
                    <text>Plasmid cotransfections expressed by WT-1, WTAR (a mutated form of WT-1), p53 and p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that was mutated and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="245">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 having the ability to be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="246">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 having the ability to be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="247">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 observed to be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="248">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that can be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="249">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that can be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="250">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that could be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="251">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that could be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="252">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that has been mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="253">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that has been notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="254">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that is notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="255">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that will be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="256">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that would be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="257">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with a 3-fold induction with WT-1, a 7-fold induction with p53 that would be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">a 7-fold induction</arg>
                </example>
                <example src="EGRAM" no="258">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 being mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="259">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 capable of being mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="260">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 observed to be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="261">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 that can be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="262">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 that could have been mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="263">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 that could have been notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="264">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 that is capable of being notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="265">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 that is mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="266">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 that is noticeably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="267">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 that will be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="268">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 that will be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="269">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 thought to be mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="270">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53 which is thought to be notably mutated, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="271">
                    <text>Plasmid cotransfections expressing WT-1, WTAR (a mutated form of WT-1), p53, and a mutated form of p53 revealed a complex regulatory pattern with an induction of 3 folds with WT-1, an induction of 7 folds with p53, and a 4-fold repression with p53.</text>
                    <arg n="0">p53</arg>
                    <arg n="2">an induction of 7 folds</arg>
                </example>
                <example src="EGRAM" no="272">
                    <text>Research showed that the A0 mutation (local site MAP C-terminal kinase (T235 and T239) could mutating essentially led to increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above increased phosphorylation stimulated by FEG and change of mobility induced by FEG</arg>
                </example>
                <example src="EGRAM" no="273">
                    <text>Snippets of template can be mutated by the SAP97 RAT sequence, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="274">
                    <text>Snippets of template is likely to be mutated by the SAP97 RAT sequence, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="275">
                    <text>Snippets of template is likely to be significantly mutated by the SAP97 RAT sequence, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">Snippets of template</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="276">
                    <text>The A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), for example, is mutate as what essentially leads to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="277">
                    <text>The A0 mutation (the C-terminal kinase sites of MAP (T235 and T239), in contrast, is mutate as what essentially leads to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="278">
                    <text>The A0 mutation (the C-terminal-Kinase sites of MAP (T235 and T239), for example, essentially mutating to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="279">
                    <text>The A0 mutation (the sites of MAP C-terminal kinase (T235 and T239), for example, may mutate essentially led to increasing above FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="280">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) in contrast leads essentially to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutate 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="281">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) in contrast leads essentially to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="282">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239) may mutating essentially led to abolited increase of EGF and increased phosphorylation and mobility induced by EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="EGRAM" no="283">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially led to abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolition of increased FEG-stimulated phosphorylation and reduction of FEG-induced mobility</arg>
                </example>
                <example src="EGRAM" no="284">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, essentially mutate to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="285">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), for example, may mutating essentially led to abolited increase of EGF and increased phosphorylation and mobility induced by EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="EGRAM" no="286">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, essentially led to abolited increase of EGF and increased phosphorylation and mobility induced by EGF (figure 5C, mutate 7 and 8).</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="EGRAM" no="287">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, essentially led to abolited increase of EGF and increased phosphorylation and mobility induced by EGF (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">abolited increase of EGF and increased phosphorylation and mobility induced by EGF</arg>
                </example>
                <example src="EGRAM" no="288">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, is mutating as one of the main responsible for abolited EGF increase and increased EGF-induced phosphorylation and mobility (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited EGF increase and increased EGF-induced phosphorylation and mobility</arg>
                </example>
                <example src="EGRAM" no="289">
                    <text>The A0 mutation (the sites of the C-terminal kinase of MAP (T235 and T239), in contrast, may mutate essentially led to abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase in FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="290">
                    <text>The A0 mutation (the sites of the MAP C-terminal kinase (T235 and T239) could mutating essentially led to the increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="EGRAM" no="291">
                    <text>The A0 mutation (the sites of the MAP C-terminal kinase (T235 and T239), for example, essentially led to above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">above the increased phosphorylation stimulated by FEG and reduced mobility induced by FEG</arg>
                </example>
                <example src="EGRAM" no="292">
                    <text>The A0 mutation (the sites of the MAP C-terminal kinase (T235 and T239), for example, essentially led to increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF (figure 5C, mutate 7 and 8).</text>
                    <arg n="2">increasing above the EGF increase and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="EGRAM" no="293">
                    <text>The A0 mutation (the sites of the MAP C-terminal kinase (T235 and T239), for example, may mutating essentially led to increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF (figure 5C, bands 7 and 8).</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="EGRAM" no="294">
                    <text>The A0 mutation (the sites of the MAP C-terminal kinase (T235 and T239), however, essentially led to the increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">increasing above the EGF and increasing the phosphorylation and mobility induced by the EGF</arg>
                </example>
                <example src="EGRAM" no="295">
                    <text>The A0 mutation (the sites of the MAP terminal C-kinase (T235 and T239) in contrast leads essentially to increasing above the stimulated phosphorylation and change of mobility induced by FEG (figure 5C, mutating 7 and 8).</text>
                    <arg n="2">increasing above the stimulated phosphorylation and change of mobility induced by FEG</arg>
                </example>
                <example src="EGRAM" no="296">
                    <text>The A1 gene is able to be mutated in Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice encoding a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis slow infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="297">
                    <text>The A1 gene mutated in late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice has encoded a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant ceroid neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="298">
                    <text>The A1 gene mutated in late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice encodes a new predefined transmembrane protein.</text>
                    <arg n="2">late infectious variant neuronal lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="299">
                    <text>The A1 gene that can be mutated in Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice encodes a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis of late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="300">
                    <text>The A1 gene that can be mutated in ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf has encoded a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid lipofuscinosis neural ceroid variation (CLN6) and in mutant mice nclf</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="301">
                    <text>The A1 gene that can be mutated in ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice encodes a new predefined transmembrane protein.</text>
                    <arg n="2">ceroid variant of late infertile neural diffufuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="302">
                    <text>The A1 gene that can be mutated in infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice has encoded a new predefined transmembrane protein.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="303">
                    <text>The A1 gene that can be mutated in infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="2">infectantyl lipofuscinosis neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="304">
                    <text>The A1 gene that can be mutated into A2 (neural ceroid change of ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid ceroid</text>
                </example>
                <example src="EGRAM" no="305">
                    <text>The A1 gene that can be mutated into infant late neural lipofuscinosis (LLC6) and in nclf mutant mice codified a new pre-directed transmembrane protein.</text>
                    <arg n="2">infant late neural lipofuscinosis (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new pre-directed transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="306">
                    <text>The A1 gene that can be mutated into lipfuscinosis of late infertile neural lipofuscinosis (LN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">lipfuscinosis of late infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="307">
                    <text>The A1 gene that has the ability to be mutated in Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice encodes a newly predicted transmembrane protein.</text>
                    <arg n="2">Lipfuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="308">
                    <text>The A1 gene that has the ability to be mutated in Slow childhood neural lipfuscinosis (CLN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">Slow childhood neural lipfuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="309">
                    <text>The A1 gene that has the ability to be mutated in late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice has encoded a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="310">
                    <text>The A1 gene that has the ability to be mutated in late infection variations in neuronal lipofuscinosis and nclf mice has encoded a new predefined transmembrane protein.</text>
                    <arg n="2">late infection variations in neuronal lipofuscinosis and nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="311">
                    <text>The A1 gene that has the ability to mutated in late neuronal lipofuscinosis and mutant nclf mice encodes a newly predicted transmembrane protein.</text>
                    <arg n="2">late neuronal lipofuscinosis and mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="312">
                    <text>The A1 gene that has the ability to mutated in late neuronal lipofuscinosis and nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">late neuronal lipofuscinosis and nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="313">
                    <text>The A1 gene that has the ability to mutated into variations of late infection in neuronal lipofuscinosis and nclf mice codified a new predefined transmembrane protein.</text>
                    <arg n="2">variations of late infection in neuronal lipofuscinosis and nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="314">
                    <text>The A1 gene that is able to be mutated in late infection variant neuronal lipofuscinosis and mutant nclf mice encodes a new predefined transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal lipofuscinosis and mutant nclf mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="315">
                    <text>The A1 gene that is able to be mutated into delayed neuronal lymphofuscinosis and nclf mutant mice codes a new predefined transmembrane protein.</text>
                    <arg n="2">delayed neuronal lymphofuscinosis and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="316">
                    <text>The A1 gene that is mutated in last infertile neural lipofuscinosis (LN6) and in nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="2">last infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="317">
                    <text>The A1 gene that is mutated mutant in Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice encodes a new predefined transmembrane protein.</text>
                    <arg n="2">Liphofuscinosis slow inphantyl neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="318">
                    <text>The A1 gene that is observed mutated in latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice has encoded a new predefined transmembrane protein.</text>
                    <arg n="2">latest infertile neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="319">
                    <text>The A1 gene that may have been mutated in late infection neuronal lipofuscinosis variant (LN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="2">late infection neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="320">
                    <text>The A1 gene that may have been mutated in late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice encodes a newly predicted transmembrane protein.</text>
                    <arg n="2">late infection variant neuronal neural lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="321">
                    <text>The A1 mutation (EE amino acids(437 and 438) in AA mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="322">
                    <text>The A1 mutation (EE amino acids(437 and 438) to AA may have mutate the DNA-binding mutant (Stat5aEE-AA) from Stat5a may have been mutate by A1 (EE amino acids(437 and 438) to AA and may have mutate the DNA-binding mutant (Stat5aEE-AA.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="323">
                    <text>The A1 mutation (EE amino acids(437 and 438) to AA mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="324">
                    <text>The A1 mutation (EE amino acids(437 and 438) to AA would mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="325">
                    <text>The A1 mutation (EE amino acids(437 and 438)) to AA is able to mutate the DNA-binding mutant (Stat5aEE-AA) of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="326">
                    <text>The A1 mutation (EE(437 and 438) amino acids to AA mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="327">
                    <text>The A1 mutation (EE(437 and 438) to AA amino acids will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="328">
                    <text>The A1 mutation (EE(437 and 438) to AA amino acids) can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="329">
                    <text>The A1 mutation (EE(437 and 438) to AA will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="330">
                    <text>The A1 mutation (EE(437 and 438)) to AA could have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="331">
                    <text>The A1 mutation (EE(437 and 438)) to AA could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="332">
                    <text>The A1 mutation (EE(437 and 438)) to AA could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="333">
                    <text>The A1 mutation (EE(437 and 438)) to AA has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="334">
                    <text>The A1 mutation (EE(437 and 438)) to AA is able to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="335">
                    <text>The A1 mutation (EE(437 and 438)) to AA is able to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="336">
                    <text>The A1 mutation (EE(437 and 438)) to AA is mutating to generate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="337">
                    <text>The A1 mutation (EE(437 and 438)) to AA is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="338">
                    <text>The A1 mutation (EE(437 and 438)) to AA may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="339">
                    <text>The A1 mutation (EE(437 and 438)) to AA may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="340">
                    <text>The A1 mutation (EE(437 and 438)) to AA may mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="341">
                    <text>The A1 mutation (EE(437 and 438)) to AA may mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="342">
                    <text>The A1 mutation (EE(437 and 438)) to AA mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="343">
                    <text>The A1 mutation (EE(437 and 438)) to AA would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="344">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a can be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="345">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a could have been mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="346">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a is mutating by the A1 mutant (EE amino acids(437 and 438)) of Stat5a is mutating by the A1 mutant (EE amino acids(437 and 438) of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="347">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a is observed to be mutating by the A1 mutation (EE amino acids(437 and 438)) to AA.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="348">
                    <text>The DNA-binding mutant (Stat5aEE-AA) of Stat5a was mutating by the A1 mutant (EE(437 and 438) of AA.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="349">
                    <text>The RCA consists of two main steps: (i) identify pairs of waste positions that could change in a coordinated manner, and (ii) use these results to identify protein regions that mutate with an unusually high number of other waste.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="EGRAM" no="350">
                    <text>The RCA consists of two main steps: (i) identify pairs of waste positions that will change in a coordinated manner, and (ii) use these results to identify protein regions that mutate with an unusually high number of other waste.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="EGRAM" no="351">
                    <text>The RCA consists of two main steps: (i) identify pairs of waste positions that would change in a coordinated manner, and (ii) use these results to identify protein regions that mutate with an unusually high number of other waste.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="EGRAM" no="352">
                    <text>The RCA consists of two main steps: (i) identifying pairs of waste positions that have changed in a coordinated manner, and (ii) using these results to identify protein regions that mutate with an unusually high number of other waste.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="EGRAM" no="353">
                    <text>The RCA consists of two main steps: (i) identifying pairs of waste positions that have mutated in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other waste.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="EGRAM" no="354">
                    <text>The RCA consists of two main steps: (i) identifying parallel of residue positions that could mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel of residue positions</arg>
                </example>
                <example src="EGRAM" no="355">
                    <text>The RCA consists of two main steps: (i) identifying parallel of residue positions that would mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel of residue positions</arg>
                </example>
                <example src="EGRAM" no="356">
                    <text>The RCA consists of two main steps: (i) identifying parallel position of waste that will change in a coordinated manner, and (ii) using these results to identify protein regions that mutate with an unusually high number of other waste.</text>
                    <arg n="1">parallel position of waste</arg>
                </example>
                <example src="EGRAM" no="357">
                    <text>The RCA consists of two main steps: (i) identifying parallel positions of residues by mutating in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel positions of residues</arg>
                </example>
                <example src="EGRAM" no="358">
                    <text>The RCA consists of two main steps: (i) identifying parallel positions of residues that mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel positions of residues</arg>
                </example>
                <example src="EGRAM" no="359">
                    <text>The RCA consists of two main steps: (i) identifying parallel positions of residues that will mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel positions of residues</arg>
                </example>
                <example src="EGRAM" no="360">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions being able to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="361">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that are able to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="362">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that are observed to change in a coordinated way, and (ii) using these results to identify protein regions that mutate with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="363">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that are observed to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="364">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that can mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="365">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that change in a coordinated way, and (ii) using these results to identify protein regions that mutate with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="366">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that could have mutated in a coordinated way, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="367">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that has mutated in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="368">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that have the ability to mutate in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="369">
                    <text>The RCA consists of two main steps: (i) identifying parallel residue positions that may have mutated in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parallel residue positions</arg>
                </example>
                <example src="EGRAM" no="370">
                    <text>The RCA consists of two main steps: (i) identifying parts of residue positions observed to mutate in a coordinated manner, and (ii) using these results to identify regions of proteins interacting with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="371">
                    <text>The RCA consists of two main steps: (i) identifying parts of residue positions that are observed to mutate in a coordinated manner, and (ii) using these results to identify regions of proteins that interact with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="372">
                    <text>The RCA consists of two main steps: (i) identifying parts of residue positions that has mutated in a coordinated way, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="373">
                    <text>The RCA consists of two main steps: (i) identifying parts of residue positions that have changed in a coordinated way, and (ii) using these results to identify protein regions that mutate with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="374">
                    <text>The RCA consists of two main steps: (i) identifying parts of residue positions that have mutated in a coordinated way, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="375">
                    <text>The RCA consists of two main steps: (i) identifying parts of residue positions that have the ability to mutate in a coordinated manner, and (ii) using these results to identify regions of proteins that interact with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="376">
                    <text>The RCA consists of two main steps: (i) identifying settlement pairs that are able to change in a coordinated way, and (ii) using these results to identify protein regions that mutate with an unusually high number of other residues.</text>
                    <arg n="1">settlement pairs</arg>
                </example>
                <example src="EGRAM" no="377">
                    <text>The RCA consists of two main steps: (i) identifying settlement pairs that have the ability to change in a coordinated way, and (ii) using these results to identify protein regions that mutate with an unusually high number of other residues.</text>
                    <arg n="1">settlement pairs</arg>
                </example>
                <example src="EGRAM" no="378">
                    <text>The RCA consists of two main steps: (i) mutateing sewage pairs capable of changing in a coordinated manner, and (ii) using these results to mutate protein regions interacting with an unusually high number of other residues.</text>
                    <arg n="1">sewage pairs</arg>
                </example>
                <example src="EGRAM" no="379">
                    <text>The RCA consists of two main steps: (i) mutating settlement pairs changing in a coordinated way, and (ii) using these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">settlement pairs</arg>
                </example>
                <example src="EGRAM" no="380">
                    <text>The RCA consists of two main steps: (i) to identify observed parts of residue positions that change in a coordinated way, and (ii) to use these results to identify protein regions that mutate with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="381">
                    <text>The RCA consists of two main steps: (i) to identify parts of residue positions that can change in a coordinated way, and (ii) to use these results to identify protein regions that mutate with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="382">
                    <text>The RCA consists of two main steps: (i) to identify parts of residue positions that may have mutated in a coordinated fashion, and (ii) to use these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="383">
                    <text>The RCA is composed of two main steps: (i) identifying pairs of waste positions that could have mutated in a coordinated manner, and (ii) using these results to identify protein regions that interact with an unusually high number of other waste.</text>
                    <arg n="1">pairs of waste positions</arg>
                </example>
                <example src="EGRAM" no="384">
                    <text>The RCA is composed of two main steps: (i) to identify parts of residue positions that will mutate in a coordinated manner, and (ii) to use these results to identify protein regions that interact with an unusually high number of other residues.</text>
                    <arg n="1">parts of residue positions</arg>
                </example>
                <example src="EGRAM" no="385">
                    <text>The RCA is formed by two main steps: (i) identifying pars of residue positions that could be mutated in a coordinated manner, and (ii) using these results to identify regions of proteins that interact with an unusually high number of other residues.</text>
                    <arg n="1">pars of residue positions</arg>
                </example>
                <example src="EGRAM" no="386">
                    <text>The analyses of in vivo transcription of agn-lacZ with dam target sequences that can be mutated support this conclusion.</text>
                    <arg n="1">dam target sequences</arg>
                </example>
                <example src="EGRAM" no="387">
                    <text>The analyses of in vivo transcription of agn-lacZ with dam target sequences that may have mutated mutations support this conclusion.</text>
                    <arg n="1">dam target sequences</arg>
                </example>
                <example src="EGRAM" no="388">
                    <text>The analysis of in vivo transcription of agn-lacZ with mutated target sequences AG mutated this conclusion.</text>
                    <arg n="1">target sequences AG</arg>
                </example>
                <example src="EGRAM" no="389">
                    <text>The exon 5 could mutate allele with the termination of the premature translation and resulted in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="390">
                    <text>The exon 5 had the ability to silence allele with the termination of the premature translation and mutate in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="391">
                    <text>The exon 5 may have mutated allele with the termination of the premature translation and resulted in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="392">
                    <text>The exon 5 mutate to be silent allele with the termination of the premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="393">
                    <text>The exon 5 observed to mutate rice with premature translation abbreviation results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="394">
                    <text>The exon 5 that can mutate allele with the termination of the premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="395">
                    <text>The exon 5 that has mutated allele with the termination of the premature translation resulted in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="396">
                    <text>The exon 5 that has the ability to mutate allele with the termination of premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="397">
                    <text>The exon 5 that is capable of mutate allele with the termination of premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="398">
                    <text>The exon 5 that is mutate mutant allele with the termination of premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="399">
                    <text>The exon 5 that may have mutated allele with the termination of the premature translation resulted in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="400">
                    <text>The exon 5 that may have mutated allele with the termination of the premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="401">
                    <text>The exon 5 that mutated allele with the termination of the premature translation resulted in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="402">
                    <text>The exon 5 that mutates allele with the termination of premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="403">
                    <text>The exon 5 was able to silence allele with the termination of the premature translation and mutate in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="404">
                    <text>The in vivo transcription analyses of Agn-lacZ with dam target sequences mutated this conclusion.</text>
                    <arg n="1">dam target sequences</arg>
                </example>
                <example src="EGRAM" no="405">
                    <text>The in vivo transcription analyses of agn-lacZ with sma target sequences mutated in line with this conclusion.</text>
                    <arg n="1">sma target sequences</arg>
                </example>
                <example src="EGRAM" no="406">
                    <text>The in vivo transcription analyses of agn-lacZ with sma target sequences that are mutations mutated this conclusion.</text>
                    <arg n="1">sma target sequences</arg>
                </example>
                <example src="EGRAM" no="407">
                    <text>The in vivo transcription analyses of agn-lacZ with sma target sequences that mutated mutations support this conclusion.</text>
                    <arg n="1">sma target sequences</arg>
                </example>
                <example src="EGRAM" no="408">
                    <text>The induction of a mutation in the A0 gene (LacI) has mutated in loss of transcriptional repression of the lacZ gene that is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="409">
                    <text>The induction of a mutation in the A0 gene (LacI) has the ability to mutated in the loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="410">
                    <text>The induction of a mutation in the A0 gene (LacI) is able to mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="411">
                    <text>The induction of a mutation in the A0 gene (LacI) may have mutated in the loss of transcriptional repression of the lacZ gene which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="412">
                    <text>The induction of a mutation in the A0 gene (LacI) may have mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="413">
                    <text>The induction of a mutation in the A0 gene (LacI) may mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="414">
                    <text>The induction of a mutation in the A0 gene (LacI) mutated in loss of transcriptional repression of the lacZ gene which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="415">
                    <text>The induction of a mutation in the A0 gene (LacI) mutated in the loss of transcriptional repression of the lacZ gene which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="416">
                    <text>The induction of a mutation in the A0 gene (LacI) mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="417">
                    <text>The induction of a mutation in the A0 gene (LacI) results in the loss of transcriptional repression of the lacZ gene which mutated the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="418">
                    <text>The induction of a mutation in the A0 gene (LacI) results in the loss of transcriptional repression of the lacZ gene, which mutated a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="419">
                    <text>The induction of a mutation in the A0 gene (LacI) will mutated in the loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="420">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, could mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="421">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, has the ability to mutated in the loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="422">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, is able to mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="423">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, may have mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="424">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, may have resulted in loss of transcriptional repression of the lacZ gene being a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="425">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, may mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="426">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, mutated in the loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="427">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, results in the loss of transcriptional repression of the lacZ gene, which mutated a mutated cell.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="428">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, results in the loss of transcriptional repression of the lacZ gene, which mutated the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="429">
                    <text>The induction of a mutation in the A0 gene (LacI), for example, will mutated in the loss of transcriptional repression of the lacZ gene, which is the cell mutation.</text>
                    <arg n="2">the loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="430">
                    <text>The induction of a mutation in the A0 gene (LacI), however, may mutated in loss of transcriptional repression of the lacZ gene, which is a mutated cell.</text>
                    <arg n="2">loss of transcriptional repression of the lacZ gene</arg>
                </example>
                <example src="EGRAM" no="431">
                    <text>The model breakdowns can be significantly mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="432">
                    <text>The model breakdowns may have been significantly mutated by the Sa97 RAT sequence, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model breakdowns</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="433">
                    <text>The model faults may have been mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="434">
                    <text>The model fragrances could have been significantly mutated by the the SAP97 RAT sequence, the adherence no.D62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="435">
                    <text>The model fragrances may have been mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="436">
                    <text>The model fragrances was mutated by the Sa97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">Sa97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="437">
                    <text>The model fragrances was significantly mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="438">
                    <text>The model fragrances will be mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="439">
                    <text>The model fragrances would be mutated by the the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="440">
                    <text>The model fragrances would be significantly mutated to the the SAP97 RAT sequence, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="441">
                    <text>The mutated A1 gene in late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice was the A3 gene (a recently predicted transmembrane protein).</text>
                    <arg n="2">late-infection neuronal ceroid lipofuscinosis (LN6) and nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="442">
                    <text>The mutation A1 (EE(437 and 438) to AA can mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="443">
                    <text>The mutation A1 (EE(437 and 438) to AA can mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="444">
                    <text>The mutation A1 (EE(437 and 438) to AA could mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="445">
                    <text>The mutation A1 (EE(437 and 438) to AA could mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="446">
                    <text>The mutation A1 (EE(437 and 438) to AA has the ability to mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="447">
                    <text>The mutation A1 (EE(437 and 438) to AA is mutating to generate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="448">
                    <text>The mutation A1 (EE(437 and 438) to AA is observed to mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="449">
                    <text>The mutation A1 (EE(437 and 438) to AA may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a may have been caused by the DNA mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="450">
                    <text>The mutation A1 (EE(437 and 438) to AA may have mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="451">
                    <text>The mutation A1 (EE(437 and 438) to AA may have mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="452">
                    <text>The mutation A1 (EE(437 and 438) to AA mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="453">
                    <text>The mutation A1 (EE(437 and 438) to AA mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="454">
                    <text>The mutation A1 (EE(437 and 438) to AA will mutate the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="455">
                    <text>The mutation A1 (EE(437 and 438) to AA will mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="456">
                    <text>The mutation A1 (EE(437 and 438) to AA would mutating the DNA-binding mutant (Stat5aEE-AA of Stat5a.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="457">
                    <text>The mutation of the sites T235 and T239, for example, is mutating to essentially lead to abolition the stimulated increase in EGF phosphorylation and preventing the change in mobility introduced by the EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the sites T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase in EGF phosphorylation and preventing the change in mobility introduced by the EGF</arg>
                </example>
                <example src="EGRAM" no="458">
                    <text>The preserved phenylalanine A1 mutation (the eh1/GEH sequence) glutamic acid mutate the binding of the snail (Jimnez et al., 1999).</text>
                    <arg n="0">preserved phenylalanine</arg>
                    <arg n="2">glutamic acid</arg>
                </example>
                <example src="EGRAM" no="459">
                    <text>The preserved phenylalanine A1 mutation (the eh1/GEH sequence) glutamic acid mutating the binding of the snail (Jimnez et al., 1999).</text>
                    <arg n="0">preserved phenylalanine</arg>
                    <arg n="2">glutamic acid</arg>
                </example>
                <example src="EGRAM" no="460">
                    <text>The research showed that the A0 mutation (local C-terminal kinase site of MAP (T235 and T239) may mutating essentially led to abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change (figure 5C, bands 7 and 8).</text>
                    <arg n="2">abolited increase of FEG-stimulated phosphorylation and FEG-induced mobility change</arg>
                </example>
                <example src="EGRAM" no="461">
                    <text>The result of the A1 mutation (EE(437 and 438) to AA is the DNA-binding mutant (Stat5aEE-AA of stad5a that is mutating.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="462">
                    <text>The result of the mutation A1 (EE(437 and 438) to AA is the DNA-binding mutant (Stat5aEE-AA of Stat5a that is mutating.</text>
                    <arg n="2">AA</arg>
                </example>
                <example src="EGRAM" no="463">
                    <text>The template fragments could be muted for the SAP97 RAT sequence, No.D62696 adhesion mutated the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="464">
                    <text>The template fragments have been mutated by the SAP97 RAT sequence, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="465">
                    <text>The template fragments have been significantly mutated by the SAP97 RAT sequence, ascent No. 62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="466">
                    <text>The template fragments may have been mutated by the SAP97 RAT sequence, Adhesion No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="467">
                    <text>The template fragments will be significantly mutated for the SAP97 RAT sequence, No.D62696 adhesion using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">The template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="468">
                    <text>The transient expression of A0 mutants (exon 8) cDNA alpha chain in COS-1 cells mutates in enzymatic activity deficiency.</text>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="469">
                    <text>The transient expression of exon 8 can mutate alpha strand cDNA DNA in cells-1, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in cells-1</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="470">
                    <text>The transient expression of exon 8 can mutate alpha strand cDNA in COS-1 cells and results in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="471">
                    <text>The transient expression of exon 8 can significantly mutate alpha cDNA chain in COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="472">
                    <text>The transient expression of exon 8 could have mutated alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="473">
                    <text>The transient expression of exon 8 could have significantly mutated alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="474">
                    <text>The transient expression of exon 8 could mutate alpha strand cDNA DNA in cells-1, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in cells-1</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="475">
                    <text>The transient expression of exon 8 could significantly mutate alpha cDNA chain in COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="476">
                    <text>The transient expression of exon 8 could significantly mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="477">
                    <text>The transient expression of exon 8 has mutated alpha strand cDNA DNA in COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="478">
                    <text>The transient expression of exon 8 has significantly mutated alpha strand cDNA DNA in COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="479">
                    <text>The transient expression of exon 8 has the ability to mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="480">
                    <text>The transient expression of exon 8 has the ability to mutate alpha strand cDNA in COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="481">
                    <text>The transient expression of exon 8 has the ability to significantly mutate alpha strand cDNA in COS-1 cells resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="482">
                    <text>The transient expression of exon 8 is able to mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="483">
                    <text>The transient expression of exon 8 is able to mutate alpha strand cDNA in COS-1 cells, resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="484">
                    <text>The transient expression of exon 8 is able to significantly mutate alpha chain cDNA in COS-1 cells resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="485">
                    <text>The transient expression of exon 8 is believed to mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="486">
                    <text>The transient expression of exon 8 is believed to mutate alpha chain cDNA in COS-1 cells significantly, resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="487">
                    <text>The transient expression of exon 8 is thought to significantly mutate alpha strand cDNA in COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="488">
                    <text>The transient expression of exon 8 may have A1 mutation (acDR DNA of the alpha chain cDNA in COS-1 cells) mutated in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="489">
                    <text>The transient expression of exon 8 may have A1 mutation (acDR DNA of the alpha chain cDNA in the 1-cells), mutated in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="490">
                    <text>The transient expression of exon 8 may have A1 mutation (alpha chain DNA in cos-1 cells), mutated in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="491">
                    <text>The transient expression of exon 8 may have mutation alpha strand cDNA in the COS-1 cells mutated in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="492">
                    <text>The transient expression of exon 8 may have significant mutation of alpha chain DNA in cells 1, mutated in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain DNA in cells 1</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="493">
                    <text>The transient expression of exon 8 may have significantly mutated acDR DNA of the alpha chain cDNA in COS-1 cells resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="494">
                    <text>The transient expression of exon 8 may have significantly mutated alpha strand cDNA in the COS-1 cells resulted in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="495">
                    <text>The transient expression of exon 8 may mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="496">
                    <text>The transient expression of exon 8 may mutate alpha chain cDNA in COS-1 cells resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="497">
                    <text>The transient expression of exon 8 mutated acDR DNA of the alpha chain cDNA in COS-1 cells, resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="498">
                    <text>The transient expression of exon 8 significantly changes alpha strand cDNA in COS-1 cells, mutates in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="499">
                    <text>The transient expression of exon 8 significantly mutated acDR DNA of the alpha chain cDNA in COS-1 cells, resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="500">
                    <text>The transient expression of exon 8 significantly mutates alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="501">
                    <text>The transient expression of exon 8 was observed to mutate alpha chain cDNA in COS-1 cells resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="502">
                    <text>The transient expression of exon 8 was observed to significantly mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="503">
                    <text>The transient expression of exon 8 was observed to significantly mutate alpha-chain cDNA into COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-chain cDNA into COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="504">
                    <text>The transient expression of exon 8 will mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="505">
                    <text>The transient expression of exon 8 will mutate alpha strand cDNA DNA in COS-1 cells results in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="506">
                    <text>The transient expression of exon 8 will significantly mutate alpha strand cDNA in COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="507">
                    <text>The transient expression of exon 8 would mutate alpha strand cDNA in the COS-1 cells, resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in the COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="508">
                    <text>The transient expression of exon 8 would mutate cDNA alpha chain in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="509">
                    <text>The transient expression of exon 8 would significantly mutate alpha chain cDNA in COS-1 cells resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="510">
                    <text>The transient expression of exon 8 would significantly mutate alpha strand cDNA in COS-1 cells resulted in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="511">
                    <text>The transient expression of mutants exon 8 alpha strand cDNA in COS-1 cells mutates in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="512">
                    <text>This epitope, which is mutate to HLA-A2, includes two amino acids that can commonly change (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="513">
                    <text>This epitope, which is mutate to HLA-A2, includes two amino acids that commonly change (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="514">
                    <text>This epitope, which is mutate to HLA-A2, includes two amino acids that commonly change (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="515">
                    <text>This epitope, which is mutate to HLA-A2, includes two amino acids that is able to commonly change (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="516">
                    <text>This epitope, which is mutate to HLA-A2, includes two amino acids that may commonly change (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="517">
                    <text>This epitope, which is mutated to HLA-A2, includes two amino acids that have been mutations (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="518">
                    <text>This epitope, which is mutated to HLA-A2, includes two amino acids that mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="519">
                    <text>This epitope, which is mutating to HLA-A2, includes the A1 mutation (two amino acids) (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="520">
                    <text>This epitope, which is mutating to HLA-A2, includes the mutation two amino acids (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="521">
                    <text>This epitope, which is mutating to HLA-A2, includes two amino acids commonly mutants (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="522">
                    <text>This epitope, which is mutating to HLA-A2, includes two amino acids that are commonly mutant (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="523">
                    <text>This epitope, which is mutating to HLA-A2, includes two amino acids that are mutants (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="524">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids mutate for mutation (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="525">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids mutate for the mutation (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="526">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids observed to frequently mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="527">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are able to mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="528">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are commonly able to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="529">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are commonly mutate for the mutation (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="530">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are mutate for mutation (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="531">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are mutate for the mutation (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="532">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are mutate mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="533">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are observed to frequently mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="534">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that are observed to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="535">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that can mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="536">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that could have been mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="537">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that has been commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="538">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that has mutated (V82A and I84V) to the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="539">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that have been commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="540">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that have been commonly mutated (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="541">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that have been mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="542">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that is able to frequently mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="543">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that is capable of mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="544">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that may have been commonly mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="545">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that may have been commonly mutated (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="546">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that may have been frequently mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="547">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that may have been mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="548">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that may have been mutated (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="549">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that may mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="550">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that mutated (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="551">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that normally mutate (V82A and I84V) to the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="552">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that will mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="553">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that will mutate (V82A and I84V) into the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="554">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids that will mutate (V82A and I84V) to the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="555">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids which is able to frequently mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="556">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids which is able to mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="557">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids which may have been frequently mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="558">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids which may have been mutated (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="559">
                    <text>This epitope, which is restricted to HLA-A2, includes two amino acids which may mutate (V82A and I84V) in the face of protease inhibitor therapy.</text>
                    <arg n="1">two amino acids</arg>
                    <arg n="3">the face of protease inhibitor therapy</arg>
                </example>
                <example src="EGRAM" no="560">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, active interaction domains in the complex was identified and mutated.</text>
                    <arg n="1">active interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="561">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, the A1 domains were identified and mutated (active interaction domains in the complex).</text>
                </example>
                <example src="EGRAM" no="562">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential driving mechanisms, for the SWI/SNF function, we mutated and change active interaction domains in the complex.</text>
                    <arg n="1">active interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="563">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, activator interaction domains in the complex were identified and mutated.</text>
                </example>
                <example src="EGRAM" no="564">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, complex activation interaction domains will be identified and mutated.</text>
                    <arg n="1">complex activation interaction domains</arg>
                </example>
                <example src="EGRAM" no="565">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, the activator interaction domains in the complex have been identified and mutated.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="566">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, the complex activator interaction domains will be identified and mutated.</text>
                    <arg n="1">the complex activator interaction domains</arg>
                </example>
                <example src="EGRAM" no="567">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we found to identify and mutate the activator interaction domains in the complex.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="568">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we have identified and mutated the activator interaction domains in the complex.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="569">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we identify and mutate the activator interaction domains in the complex.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="570">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we identify and mutated the activator interaction domains in the complex.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="571">
                    <text>To determine how activators interact with the complex and examine the importance of these interactions, in relation to other potential orientation mechanisms, for the SWI/SNF function, we will identify and mutate the activator interaction domains in the complex.</text>
                    <arg n="1">the activator interaction domains in the complex</arg>
                </example>
                <example src="EGRAM" no="572">
                    <text>To mutate a preserved phenylalanine from the sequence eh1/GEH to glutamic acid abolished the binding of groucho (Jimnez et al., 1999).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                    <arg n="2">to glutamic acid</arg>
                </example>
                <example src="EGRAM" no="573">
                    <text>To mutate the MAP-terminal T235 and T239 sites, for example, has essentially led to abolition the stimulated increase in the EGF in phosphorylation and preventing the change in mobility introduced by the EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase in the EGF in phosphorylation and preventing the change in mobility introduced by the EGF</arg>
                </example>
                <example src="EGRAM" no="574">
                    <text>To mutate the MAP-terminal T235 and T239 sites, for example, it is observed that it essentially leads to abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="575">
                    <text>To mutate the MAP-terminal T235 and T239 sites, for example, may have essentially led to abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="576">
                    <text>To mutate the MAP-terminal T235 and T239 sites, however, it could have essentially led to abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF (Figure 5C, lanes 7 and 8).</text>
                    <arg n="0">the MAP-terminal T235 and T239</arg>
                    <arg n="2">abolition the stimulated increase of EGF in phosphorylation and preventing the change in mobility introduced by EGF</arg>
                </example>
                <example src="EGRAM" no="577">
                    <text>Transient expression of exon 8 has the ability to significantly mutate acDR-alpha in the alpha chain of cells 1, resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR-alpha in the alpha chain of cells 1</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="578">
                    <text>Transient expression of exon 8 is able to significantly mutate alpha-acDR in the alpha chain in 1-BODY cells results in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha-acDR in the alpha chain in 1-BODY cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="579">
                    <text>Transient expression of exon 8 is observed for A1 mutation (acDR DNA of alpha chain cDNA in 1 cells), mutate in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="580">
                    <text>Transient expression of exon 8 is thought to mutate acDR DNA of the alpha chain cDNA in the 1-cells, resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in the 1-cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="581">
                    <text>Transient expression of exon 8 may significantly mutate alpha chain cDNA in COS-1 cells resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="582">
                    <text>Transient expression of exon 8 will significantly mutate alpha chain cDNA in COS-1 cells resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="583">
                    <text>We have identified five hydrophobic amino acid residues in extracellular domain ALK4 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when completely mutated to alanine, has substantial effects on the dominant negative activity alK4-trunc.</text>
                    <arg n="0">extracellular domain ALK4</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has substantial effects on the dominant negative activity alK4-trunc</arg>
                </example>
                <example src="EGRAM" no="584">
                    <text>We have identified five hydrophobic amino acid residues in extracellular domain ALK4 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when completely mutated to alanine, having substantial effects on the dominant negative activity alK4-trunc.</text>
                    <arg n="0">extracellular domain ALK4</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">having substantial effects on the dominant negative activity alK4-trunc</arg>
                </example>
                <example src="EGRAM" no="585">
                    <text>We have identified five hydrophobic amino acid residues in extracellular domain ALK4 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when mutated to alanine, has substantial effects on the dominant negative activity alK4-trunc.</text>
                    <arg n="0">extracellular domain ALK4</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has substantial effects on the dominant negative activity alK4-trunc</arg>
                </example>
                <example src="EGRAM" no="586">
                    <text>We have identified five hydrophobic amino acid residues in extracellular domain ALK4 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when mutated to alanine, having substantial effects on the dominant negative activity alK4-trunc.</text>
                    <arg n="0">extracellular domain ALK4</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">having substantial effects on the dominant negative activity alK4-trunc</arg>
                </example>
                <example src="EGRAM" no="587">
                    <text>We have identified five hydrophobic amino acid residues in extracellular domain ALK4 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when significantly mutated to alanine, has substantial effects on the dominant negative activity alK4-trunc.</text>
                    <arg n="0">extracellular domain ALK4</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has substantial effects on the dominant negative activity alK4-trunc</arg>
                </example>
                <example src="EGRAM" no="588">
                    <text>We have identified five hydrophobic amino acid residues in extracellular domain ALK4 (Leu40, Ile70, Val73, Leu75, and Pro77) which, when significantly mutated to alanine, having substantial effects on the dominant negative activity alK4-trunc.</text>
                    <arg n="0">extracellular domain ALK4</arg>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">having substantial effects on the dominant negative activity alK4-trunc</arg>
                </example>
                <example src="EGRAM" no="589">
                    <text>We identify five hydrophobic amino acid residues in the A0 domain (extracellular ALK4 domain) (Leu40, Ile70, Val73, Leu75 and Pro77) which, when mutated to alanine, has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="EGRAM" no="590">
                    <text>We identify five hydrophobic amino acid residues in the A0 domain (extracellular ALK4 domain) (Leu40, Ile70, Val73, Leu75 and Pro77) which, when significantly mutated to alanine, has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five hydrophobic amino acid residues</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="EGRAM" no="591">
                    <text>We identify five residues of hydrophobic amino acids in the A0 domain (extracellular ALK4 domain) (Leu40, Ile70, Val73, Leu75 and Pro77) which, when completely mutated to alanine, has significant effects on the dominant negative activity of ALK4-trunc.</text>
                    <arg n="1">five residues of hydrophobic amino acids</arg>
                    <arg n="2">alanine</arg>
                    <arg n="3">has significant effects on the dominant negative activity of ALK4-trunc</arg>
                </example>
                <example src="EGRAM" no="592">
                    <text>a gene that can be mutated in variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice was A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="593">
                    <text>a gene that has been mutated into late neural lipofuscinosis variant (LLC6) and nclf mutant mice encodes a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neural lipofuscinosis variant (LLC6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="594">
                    <text>a gene that has been mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice codes a new transmembrane protein predicted.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="EGRAM" no="595">
                    <text>a gene that is able to be mutated in late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice codes a new transmembrane protein predicted.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="EGRAM" no="596">
                    <text>a gene that is mutated into late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice codes an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="597">
                    <text>a gene that is observed to be mutated in late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice codes an unprecedented transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="598">
                    <text>a gene that may have been mutated in delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="599">
                    <text>a gene that may have been mutated in variate to the variant of cerebroide neuronal lipofuscinosis (CLN6) and nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">variate to the variant of cerebroide neuronal lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="600">
                    <text>a gene that was mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice was a new predicted transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="601">
                    <text>a gene that will be mutated into delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="602">
                    <text>a gene that will mutated in variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice was a new predefined transmembrane protein.</text>
                    <arg n="1">a gene</arg>
                    <arg n="2">variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="603">
                    <text>a mutated gene in variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice encodes A3 (a new mutated transmembrane protein.</text>
                    <arg n="1">a mutated gene</arg>
                    <arg n="2">variant under the neural lipofuscinosis variant cerebroide (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="604">
                    <text>acDR DNA of alpha chain cDNA in COS-1 cells is able to be mutated by the transient expression of exon 8 results in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="605">
                    <text>acDR DNA of alpha chain cDNA in COS-1 cells is able to be significantly mutated by the transient expression of exon 8 results in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="606">
                    <text>acDR DNA of alpha chain cDNA in COS-1 cells was mutated by transient expression of exon 8 resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="607">
                    <text>acDR DNA of alpha chain cDNA in COS-1 cells was significantly mutated by transient expression of exon 8 resulted in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="608">
                    <text>acDR DNA of alpha chain cDNA in COS-1 cells was significantly mutated by transient expression of exon 8 resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="609">
                    <text>acDR DNA of the alpha chain cDNA in COS-1 cells was mutated by the transient expression of exon 8 resulting in enzymatic deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">acDR DNA of the alpha chain cDNA in COS-1 cells</arg>
                    <arg n="3">enzymatic deficiency</arg>
                </example>
                <example src="EGRAM" no="610">
                    <text>alpha cDNA chain in COS-1 cells can be mutated by the transient expression of exon 8 resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="611">
                    <text>alpha cDNA chain in COS-1 cells can be significantly mutated by the transient expression of exon 8 resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="612">
                    <text>alpha cDNA chain in COS-1 cells can be significantly mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="613">
                    <text>alpha cDNA chain in COS-1 cells has the ability to be significantly mutated by the transient expression of exon 8 results in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="614">
                    <text>alpha cDNA chain in COS-1 cells is likely to be mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="615">
                    <text>alpha cDNA chain in COS-1 cells is likely to be significantly mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="616">
                    <text>alpha cDNA chain in COS-1 cells is significantly mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="617">
                    <text>alpha cDNA chain in COS-1 cells may have been mutated by the transient expression of exon 8 resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="618">
                    <text>alpha cDNA chain in COS-1 cells may have been significantly mutated by the transient expression of exon 8 resulting in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="619">
                    <text>alpha cDNA chain in COS-1 cells would be mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="620">
                    <text>alpha cDNA chain in COS-1 cells would be significantly mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="621">
                    <text>alpha cDNA chain in the COS-1 cells is mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha cDNA chain in the COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="622">
                    <text>alpha strand cDNA DNA in COS-1 cells has been mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="623">
                    <text>alpha strand cDNA DNA in COS-1 cells has been significantly mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="624">
                    <text>alpha strand cDNA DNA in COS-1 cells may have been mutated by the transient expression of exon 8 resulting in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in COS-1 cells</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="625">
                    <text>alpha strand cDNA DNA in cells-1 has the ability to be mutated by the transient expression of exon 8 results in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in cells-1</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="626">
                    <text>alpha strand cDNA DNA in cells-1 is observed to be significantly mutated by the transient expression of exon 8 results in enzyme deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">alpha strand cDNA DNA in cells-1</arg>
                    <arg n="3">enzyme deficiency</arg>
                </example>
                <example src="EGRAM" no="627">
                    <text>cDNA alpha chain in COS-1 cells can be mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="628">
                    <text>cDNA alpha chain in COS-1 cells can be significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="629">
                    <text>cDNA alpha chain in COS-1 cells could have been mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="630">
                    <text>cDNA alpha chain in COS-1 cells could have been significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="631">
                    <text>cDNA alpha chain in COS-1 cells has the ability to be mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="632">
                    <text>cDNA alpha chain in COS-1 cells has the ability to be significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="633">
                    <text>cDNA alpha chain in COS-1 cells is able to be mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="634">
                    <text>cDNA alpha chain in COS-1 cells is able to be significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="635">
                    <text>cDNA alpha chain in COS-1 cells is likely to be mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="636">
                    <text>cDNA alpha chain in COS-1 cells is likely to be significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="637">
                    <text>cDNA alpha chain in COS-1 cells is significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="638">
                    <text>cDNA alpha chain in COS-1 cells may have been mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="639">
                    <text>cDNA alpha chain in COS-1 cells may have been significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="640">
                    <text>cDNA alpha chain in COS-1 cells was mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="641">
                    <text>cDNA alpha chain in COS-1 cells was significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="642">
                    <text>cDNA alpha chain in COS-1 cells will be mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="643">
                    <text>cDNA alpha chain in COS-1 cells will be significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="644">
                    <text>cDNA alpha chain in COS-1 cells would be mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="645">
                    <text>cDNA alpha chain in COS-1 cells would be significantly mutated by the transient expression of exon 8 resulted in enzymatic activity deficiency.</text>
                    <arg n="0">exon 8</arg>
                    <arg n="1">cDNA alpha chain in COS-1 cells</arg>
                    <arg n="3">enzymatic activity deficiency</arg>
                </example>
                <example src="EGRAM" no="646">
                    <text>exon 5 can mutate allele with termination of premature translation and results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="647">
                    <text>exon 5 could mutate alele with finishing of premature translation and resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="648">
                    <text>exon 5 had the ability to mutate rice with premature translation termination and resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="649">
                    <text>exon 5 had the probability of A1 mutation (rhino) with premature translation termination and mutating in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="650">
                    <text>exon 5 had the probability of mutating allele with the termination of the premature translation and resulted in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="651">
                    <text>exon 5 is able to silencing alele with finishing of premature translation mutate in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="652">
                    <text>exon 5 is capable of silencing allele with the termination of premature translation mutate in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="653">
                    <text>exon 5 is mutating allele with termination of premature translation and resulting in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="654">
                    <text>exon 5 may have mutated alele with finishing of premature translation and resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="655">
                    <text>exon 5 may mutate alele with termination of premature translation and result in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">termination of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="656">
                    <text>exon 5 mutated alele with premature translation termination and resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="657">
                    <text>exon 5 mutated allele with the termination of premature translation and resulted in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="658">
                    <text>exon 5 mutates alele with finishing of premature translation and results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="659">
                    <text>exon 5 mutates allele with the termination of premature translation and results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="660">
                    <text>exon 5 mutates allele with the termination of the premature translation and results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of the premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="661">
                    <text>exon 5 mutating A1 mutant with termination of premature translation and results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="2">termination of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="662">
                    <text>exon 5 observed mutar allele with the termination of premature translation mutate in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="663">
                    <text>exon 5 that is able to mutate alele with finishing of premature translation results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="664">
                    <text>exon 5 that is observed to mutate rice with premature translation abbreviation results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="665">
                    <text>exon 5 that may have mutated alele with finishing of premature translation resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="666">
                    <text>exon 5 that may have mutated rice with premature translation abbreviation results in deficiency of each Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">deficiency of each Hex A</arg>
                </example>
                <example src="EGRAM" no="667">
                    <text>exon 5 that may mutate alele with finishing of premature translation results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="668">
                    <text>exon 5 that mutate allele with the termination of premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="669">
                    <text>exon 5 that mutated alele with finishing of premature translation resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="670">
                    <text>exon 5 that mutated alele with premature translation termination resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="671">
                    <text>exon 5 that mutates allele with the termination of premature translation results in serious Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">allele</arg>
                    <arg n="2">the termination of premature translation</arg>
                    <arg n="3">serious Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="672">
                    <text>exon 5 that will mutate rice with premature translation abbreviation will result in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="673">
                    <text>exon 5 was able to mutate rice with premature translation termination and resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="674">
                    <text>exon 5 was observed to mutate rice with premature translation termination and resulted in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation termination</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="675">
                    <text>exon 5 which can mutate rice with premature translation abbreviation results in deficiency of each Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">deficiency of each Hex A</arg>
                </example>
                <example src="EGRAM" no="676">
                    <text>exon 5 which has the ability to mutate alele with finishing of premature translation results in severe Hex A deficiency.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">alele</arg>
                    <arg n="2">finishing of premature translation</arg>
                    <arg n="3">severe Hex A deficiency</arg>
                </example>
                <example src="EGRAM" no="677">
                    <text>exon 5 which mutates rice with premature translation abbreviation results in deficiency of each Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">deficiency of each Hex A</arg>
                </example>
                <example src="EGRAM" no="678">
                    <text>exon 5 which mutating rice with premature translation abbreviation results in deficiency of each Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">deficiency of each Hex A</arg>
                </example>
                <example src="EGRAM" no="679">
                    <text>exon 5 will mutate rice with premature translation abbreviation and result in deficiency of each Hex A.</text>
                    <arg n="0">exon 5</arg>
                    <arg n="1">rice</arg>
                    <arg n="2">premature translation abbreviation</arg>
                    <arg n="3">deficiency of each Hex A</arg>
                </example>
                <example src="EGRAM" no="680">
                    <text>gen mutated in infant-child neural lipofuscinosis (CLN6) and in nclf mutant mice was coded in a recently predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">infant-child neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="681">
                    <text>gen that has been mutated in Lipfuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice has encoded a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">Lipfuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="682">
                    <text>gen that is mutated in Lipfuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice has encoded a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">Lipfuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="683">
                    <text>gen that is mutated in late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice was coded in a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late lipidscinosis infertile neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="684">
                    <text>gen that is mutated in slow childhood neural lipidscinosis (CLN6) and in nclf mutant mice codes a recently predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">slow childhood neural lipidscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a recently predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="685">
                    <text>gen that was mutated in Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice encodes a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="686">
                    <text>gen that will be mutated in late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice encodes a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">late infectious variant lipofuscinosis neuronal lipofuscinosis (CLN6) and in mutant nclf mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="687">
                    <text>gen was mutated in Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice has encoded a newly predicted transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">Liphofuscinosis late infertile neural lipofuscinosis (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a newly predicted transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="688">
                    <text>gen was mutated in variant of late infantyl neural lipofuscinosis (CLN6) and nclf mutant mice encoding a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">variant of late infantyl neural lipofuscinosis (CLN6) and nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="689">
                    <text>gen was mutated into the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice coding a new predefined transmembrane protein.</text>
                    <arg n="1">gen</arg>
                    <arg n="2">the variant of late infant neural lipofuscinosis (LN6) and in nclf mutant mice</arg>
                    <arg n="3">a new predefined transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="690">
                    <text>gene that has the ability to be mutated in delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was the one that codified A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="691">
                    <text>gene that is able to be mutated in delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice was the one that codified A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="692">
                    <text>gene that was mutated into delayed neuronal cerebro-infant lipofuscinosis (CLN6) variant and in nclf mutant mice was A3 (a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebro-infant lipofuscinosis (CLN6) variant and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="693">
                    <text>gene that was mutated into delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice codes a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="EGRAM" no="694">
                    <text>gene that was mutated into late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice was an unprecedented transmembrane protein.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LN6) and in nclf mutant mice</arg>
                    <arg n="3">an unprecedented transmembrane protein</arg>
                </example>
                <example src="EGRAM" no="695">
                    <text>gene that will be mutated into delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice codes a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">delayed neuronal cerebroid lipofuscinosis variant (CLN6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="EGRAM" no="696">
                    <text>gene was mutated into late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice and coded into a new transmembrane protein predicted.</text>
                    <arg n="1">gene</arg>
                    <arg n="2">late neuronal lipofuscinosis variant (LLC6) and in nclf mutant mice</arg>
                    <arg n="3">a new transmembrane protein predicted</arg>
                </example>
                <example src="EGRAM" no="697">
                    <text>genus mutated in dissipated neural lipofuscinosis induced by cerebro-cerebro (CLN6) variant and in nclf mutant mice was A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">genus</arg>
                    <arg n="2">dissipated neural lipofuscinosis induced by cerebro-cerebro (CLN6) variant and in nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="698">
                    <text>genus that can be mutated in neuronal variant lipofuscinosis cerebroide (CLN6) and nclf mutant mice was the one that encoded A3 (a newly predicted transmembrane protein.</text>
                    <arg n="1">genus</arg>
                    <arg n="2">neuronal variant lipofuscinosis cerebroide (CLN6) and nclf mutant mice</arg>
                </example>
                <example src="EGRAM" no="699">
                    <text>model faults are mutated by the SAP97 RAT sequence, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="700">
                    <text>model faults are observed mutated by the SAP97 RAT sequence, adhering to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="701">
                    <text>model faults are observed significantly mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="702">
                    <text>model faults are significantly mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model faults</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="703">
                    <text>model fragrances can be mutated by the SAP97 RAT sequence, adhesion to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="704">
                    <text>model fragrances can be significantly mutated by the SAP97 RAT sequence, adhesion in Q62696 using the Swiss PDB display software (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="705">
                    <text>model fragrances could be significantly mutated by the SAP97 RAT sequence, adherence to Q62696 using the Swiss PDB display program (Guex and Peitsch, 1997).</text>
                    <arg n="0">model fragrances</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
                <example src="EGRAM" no="706">
                    <text>mutating a preserved phenylalanine of the sequence eh1/GEH to glutamic acid abolished the binding of groucho (Jimnez et al., 1999).</text>
                    <arg n="0">a preserved phenylalanine</arg>
                    <arg n="1">the sequence eh1/GEH</arg>
                    <arg n="2">to glutamic acid</arg>
                </example>
                <example src="EGRAM" no="707">
                    <text>snippets of template can be mutated by the sequence sAP97 RAT, adherence no.D62696 using the Swiss PDB Viewer software (Guex and Peitsch, 1997).</text>
                    <arg n="0">snippets of template</arg>
                    <arg n="1">sAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="708">
                    <text>snippets of template can be significantly mutated by the sequence sAP97 RAT, adherence no.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">snippets of template</arg>
                    <arg n="1">sAP97 RAT</arg>
                </example>
                <example src="EGRAM" no="709">
                    <text>the template fragments are observed significantly mutated by the SAP97 RAT sequence, ascension No.D62696 using the Swiss PDB Viewer program (Guex and Peitsch, 1997).</text>
                    <arg n="0">the template fragments</arg>
                    <arg n="1">the SAP97 RAT sequence</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
